Practice-Based Evidence: Profiling the Safety of Cilostazol by Text-Mining of Clinical Notes

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Leeper, Nicholas J ^a   Bauer Mehren, Anna ^b   Iyer, Srinivasan V ^b   LePendu, Paea ^b   Olson, Cliff ^c   Shah, Nigam H ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DATA ANALYSIS; DATA MINING; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; SUDDEN CARDIAC DEATH;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DATA MINING; FEMALE; HEART FAILURE; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PHOSPHODIESTERASE 3 INHIBITORS; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; RISK; TETRAZOLES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84878134737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063499     Document Type: Article

References (38)

1. Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, et al. (2008) One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 1: 38-45.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, et al. (2001) Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286: 1317-1324.
3. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, et al. (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297: 1197-1206.
4. Wilson AM, Sadrzadeh-Rafie AH, Myers J, Assimes T, Nead KT, et al. (2011) Low lifetime recreational activity is a risk factor for peripheral arterial disease. J Vasc Surg 54: 427-432, 432 e421-424.
5. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, et al. (2008) The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med 13: 15-24.
6. McDermott MM, Greenland P, Guralnik JM, Liu K, Criqui MH, et al. (2003) Depressive symptoms and lower extremity functioning in men and women with peripheral arterial disease. J Gen Intern Med 18: 461-467.
7. Hirschhorn JN, Daly MJ, (2005) Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6: 95-108.
8. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, et al. (1999) A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 159: 2041-2050.
9. Reilly MP, Mohler ER, (2001) Cilostazol: treatment of intermittent claudication. Ann Pharmacother 35: 48-56.
10. Thompson PD, Zimet R, Forbes WP, Zhang P, (2002) Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90: 1314-1319.
11. Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA, (2010) A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 15: 181-188.
12. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1468-1475.
13. Chi YW, Lavie CJ, Milani RV, White CJ, (2008) Safety and efficacy of cilostazol in the management of intermittent claudication. Vasc Health Risk Manag 4: 1197-1203.
14. Hiatt WR, Money SR, Brass EP, (2008) Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 47: 330-336.
15. LePendu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, et al. (2013) Pharmacovigilance Using Clinical Notes. Clin Pharmacol Ther.
16. Lependu P, Iyer SV, Fairon C, Shah NH, (2012) Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes. J Biomed Semantics 3Suppl 1: S5.
17. Shah NH, Bhatia N, Jonquet C, Rubin D, Chiang AP, et al. (2009) Comparison of concept recognizers for building the Open Biomedical Annotator. BMC Bioinf 10Suppl 9: S14.
18. Lependu P, Liu Y, Iyer S, Udell MR, Shah NH, (2012) Analyzing patterns of drug use in clinical notes for patient safety. AMIA Summits Transl Sci Proc 2012: 63-70.
19. Bodenreider O, McCray AT, (2003) Exploring semantic groups through visual approaches. J Biomed Inf 36: 414-432.
20. Xu R, Musen MA, Shah NH, (2010) A Comprehensive Analysis of Five Million UMLS Metathesaurus Terms Using Eighteen Million MEDLINE Citations. AMIA Annu Symp Proc 2010: 907-911.
21. Parai GK, Jonquet C, Xu R, Musen MA, Shah NH, (2010) The Lexicon Builder Web service: Building Custom Lexicons from two hundred Biomedical Ontologies. AMIA Annu Symp Proc 2010: 587-591.
22. Wu ST, Liu H, Li D, Tao C, Musen MA, et al. (2012) Unified Medical Language System term occurrences in clinical notes: a large-scale corpus analysis. J Am Med Inform Assoc.
23. Chapman WW, Bridewell W, Hanbury P, Cooper GF, Buchanan BG, (2001) A simple algorithm for identifying negated findings and diseases in discharge summaries. J Biomed Inform 34: 301-310.
24. Chapman WW, Chu D, Dowling JN (2007) ConText: An Algorithm for Identifying Contextual Features from Clinical Text. Workshop on BioNLP 2007: Biological, Translational, and Clinical Language Processing: 1-8.
25. Uzuner O, (2009) Recognizing obesity and comorbidities in sparse data. J Am Med Inform Assoc 16: 561-570.
26. Marshall MS, Boyce R, Deus HF, Zhao J, Willighagen EL, et al. (2012) Emerging practices for mapping and linking life sciences data using RDF - A case series. Web Semantics: Science, Services and Agents on the World Wide Web 14: 2-13.
27. Sekhon JS (2011) Multivariate and Propensity Score Matching Software with Automated Balance Optimization The Matching Package for R. Journal of Statistical Software 42.
28. Gail MH, Lubin JH, Rubinstein LV, (1981) Likelihood calculations for matched case-control studies and survival studies with tied death times. Biometrika 68: 703-707.
29. Thernau T (2012) A Package for Survival Analysis in S.
30. Robless P, Mikhailidis DP, Stansby GP (2008) Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev: CD003748.
31. Pratt CM, (2001) Analysis of the cilostazol safety database. Am J Cardiol 87: 28D-33D.
32. Frankovich J, Longhurst CA, Sutherland SM, (2011) Evidence-based medicine in the EMR era. N Engl J Med 365: 1758-1759.
33. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, et al. (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324: 781-788.
34. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
35. Liu Y, Lependu P, Iyer S, Shah NH, (2012) Using temporal patterns in medical records to discern adverse drug events from indications. AMIA Summits Transl Sci Proc 2012: 47-56.
36. Alvarez-Fernandez LJ, Vallina-Victorero Vazquez MJ, Ramos Gallo MJ, Santiago MV, (2009) [Implications of the REACH registry for vascular surgery]. Med Clin (Barc) 132Suppl 2: 25-29.
37. Mechtouff L, Touze E, Steg PG, Ohman EM, Goto S, et al. (2010) Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease. J Intern Med 267: 621-633.
38. Margolis J, Barron JJ, Grochulski WD, (2005) Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm 11: 727-734.